J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.